LncRNAs in cardiac hypertrophy: From basic science to clinical application

Lei Liu | Donghui Zhang | Yifei Li

INTRODUCTION

Cardiac hypertrophy is considered as a pathological phenotype of cardiomyopathy and as a result from pathological remodelling of cardiomyocytes in humans. At present, emerging evidence demonstrated the roles of long non-coding RNAs (lncRNAs) in regulating the pathophysiologic process of cardiac hypertrophy. In this review, we will discuss the recent researches on this issue and try to analyse the potential therapeutic targets on lncRNA sites. Studies have revealed both genetic mutations related hypertrophic cardiomyopathy and the compensative cardiac hypertrophy due to pressure overload, inflammation, endocrine issues and other external stimulations, share a common molecular mechanism of ventricular hypertrophy. The emerging evidence identified the abnormal expression of lncRNAs would leading to the impairment the function of sarcomere, intracellular calcium handling and mitochondrial metabolisms. Several researches proved the therapeutic role of lncRNAs in preventing or reversing cardiac hypertrophy. With the development of delivery system for small pieces of oligonucleotide, clinicians could design gene therapy approaches to terminate the process of cardiac hypertrophy to provide better prognosis.

KEYWORDS

cardiac hypertrophy, cardiomyocytes remodelling, long non-coding RNA, targeting therapy
a common molecular mechanism of ventricular hypertrophy, which is associated with the sustain cardiac output, and chronically sustained stimulation of undesirable factors would deteriorate the pumping capacity of cardiac, causing multifactorial clinical syndrome, even heart failure. These compensatory and deteriorate changes in cardiomyocyte are associated with re-expression of foetal genes, which are mainly related to sarcomere contraction, ion signal regulation and activity, and mitochondrial function. Increased myofilament Ca\textsuperscript{2+} sensitivity has been identified in animal model and patients with pathological hypertrophy, leading changes of intracellular Ca\textsuperscript{2+} homoeostasis and causing Ca\textsuperscript{2+}-triggered arrhythmias, which could increase force development and adenosine triphosphate (ATP) consumption. Mitochondrial disorganization and dysfunction in cardiac hypertrophy could cause energy supply and demands imbalance. Clarifying the regulator network of sarcomere contraction, calcium handling and mitochondrial function would benefit the working of finding a new and common target for the treatment of cardiac hypertrophy.

Only 2% of billions DNA bases coding for proteins indicates non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), acting as vital roles in physiology and pathology. MiRNAs, approximately 22 nucleotides in length, are involved in various signalling pathways to regulate pathological cardiac remoulding, such as cardiac hypertrophy, cardiac fibrosis and myocardial infarction. Meanwhile, lncRNAs could regulate cardiac pathological processes through multiple molecular mechanisms in cis and trans, which are transcribed RNA molecules >200 nucleotides in length but have no potential for protein coding. More and more studies found that lncRNAs might act an important role to regulate the intracellular calcium handling, metabolic state in various cardiovascular diseases, including HCM (Table 1).

In this review, we mainly present an overview to clarify the role of lncRNAs in the pathological process of cardiac hypertrophy further to benefit the work on targeting therapy.

### Key points

1. Several lncRNAs participate in the regulation of pathological process in cardiac hypertrophy, interacting with the genes involving sarcomere, mitochondria and intracellular calcium transition.
2. Current evidence demonstrates the lncRNAs could be a promising target to attenuate the process of cardiac hypertrophy or even reverse the pathological phenotype. And a series of animal and few large animal experiments have been done to identified the potential activity of particular lncRNAs as a treatment alternation.
3. Non-viral and viral strategies are the most common concepts to realize the gene therapy. A set of preclinical experiments identified the capability of lncRNAs in treating cardiac hypertrophy. And this review illustrates a completed practical process to validate an lncRNA-based gene therapy from basic science to clinical application.

### 2 | MOLECULAR BASIS OF CARDIOMYOCYTE HYPERTROPHY ASSOCIATED WITH LNCRNAS

Cardiac performance is relied on Ca\textsuperscript{2+} and ATP, to pump blood to meet the energy demands of peripheral tissues, which depends filaments of sarcomere sliding. Sarcomere is the basic functional unit of the cardiomyocyte, made up by the thin and thick filaments containing a set of proteins. The thin filament is mainly consisting of α-actin, troponin complex (Tn) containing TnT, TnC, Tnl and troponymosin. The thick filament is mainly composed of myosin heavy

| LncRNA | Expression | Regulated genes | Pathophysiological mechanism | Methods to generate gain or loss function of lncRNAs | Disease model |
|--------|------------|-----------------|-----------------------------|-----------------------------------------------|---------------|
| Mhrt\textsuperscript{21} | ↓ | Brg1 | Chromatin remodelling | Mhrt- KI | mice-TAC |
| Chaer\textsuperscript{24} | ↑ | PRC2 | Epigenetic checkpoint | Chaer-KO | mice-TAC |
| MEG3\textsuperscript{35} | ↑ | miR-361-5p/HDAC9 | Epigenetic regulation | sh-MEG3 | mice-TAC/cardiomyocytes-Ang-II |
| DACH1\textsuperscript{31} | ↑ | SERCA2a | Ca\textsuperscript{2+} handling | Ad-Si-DACH1 | mice-TAC |
| H19\textsuperscript{37} | ↓ | miR-675-CaMKIId | Ca\textsuperscript{2+} handling | Ad-H19 | mice-TAC/cardiomyocytes -PE |
| Plscr4\textsuperscript{46} | ↑ | miR-214-Mfn2 | Mitochondria biological | AAV9- Plscr4 | mice-TAC/cardiomyocytes -Ang-II |
| SNHG1\textsuperscript{58} | ↑ | miR-15a-5p-HMG1A | Mitochondria biological | pcDNA-SNHG1 | mice-TAC/cardiomyocytes -PE |
| TINCR\textsuperscript{56} | ↓ | EZH2- CaMKII | epigenetic regulation/ Ca\textsuperscript{2+} handling | lentivirus-pcDNA-TINCR | mice-TAC |
| Uc.323\textsuperscript{49} | ↓ | EZH2-CPT1b | Epigenetic regulation/ mitochondria biological | lentivirus- pcDNA- Uc.323 | mice-TAC/cardiomyocytes -PE |
| Ahit\textsuperscript{52} | ↑ | SUZ12/PRC2-MEF2A | Epigenetic regulation/ Ca\textsuperscript{2+} handling/ mitochondria biological | pcDNA-Ahit | mice-TAC/cardiomyocytes -PE |

### Table 1

| LncRNA | Expression | Regulated genes | Pathophysiological mechanism | Methods to generate gain or loss function of lncRNAs | Disease model |
|--------|------------|-----------------|-----------------------------|-----------------------------------------------|---------------|
| Mhrt\textsuperscript{21} | ↓ | Brg1 | Chromatin remodelling | Mhrt- KI | mice-TAC |
| Chaer\textsuperscript{24} | ↑ | PRC2 | Epigenetic checkpoint | Chaer-KO | mice-TAC |
| MEG3\textsuperscript{35} | ↑ | miR-361-5p/HDAC9 | Epigenetic regulation | sh-MEG3 | mice-TAC/cardiomyocytes-Ang-II |
| DACH1\textsuperscript{31} | ↑ | SERCA2a | Ca\textsuperscript{2+} handling | Ad-Si-DACH1 | mice-TAC |
| H19\textsuperscript{37} | ↓ | miR-675-CaMKIId | Ca\textsuperscript{2+} handling | Ad-H19 | mice-TAC/cardiomyocytes -PE |
| Plscr4\textsuperscript{46} | ↑ | miR-214-Mfn2 | Mitochondria biological | AAV9- Plscr4 | mice-TAC/cardiomyocytes -Ang-II |
| SNHG1\textsuperscript{58} | ↑ | miR-15a-5p-HMG1A | Mitochondria biological | pcDNA-SNHG1 | mice-TAC/cardiomyocytes -PE |
| TINCR\textsuperscript{56} | ↓ | EZH2- CaMKII | epigenetic regulation/ Ca\textsuperscript{2+} handling | lentivirus-pcDNA-TINCR | mice-TAC |
| Uc.323\textsuperscript{49} | ↓ | EZH2-CPT1b | Epigenetic regulation/ mitochondria biological | lentivirus- pcDNA- Uc.323 | mice-TAC/cardiomyocytes -PE |
| Ahit\textsuperscript{52} | ↑ | SUZ12/PRC2-MEF2A | Epigenetic regulation/ Ca\textsuperscript{2+} handling/ mitochondria biological | pcDNA-Ahit | mice-TAC/cardiomyocytes -PE |
chains (MHC), myosin binding protein C (MBPC), and two light chains including regulatory myosin light chain (RLC) and essential light chain (ELC). Myosin filaments are direct link to Z-line and central of sarcomere, respectively, by protein titin and MBPC (Figure 1).\textsuperscript{17,18}

TnC could be activated by calcium-induced calcium release (CICR), inducing a conformational change in the Tn complex, resulting tropomyosin out of its groove on the actin filament, leading actin filament exposed. Myosin heads also named cross-bridges, with the binding domain of ATP, can interact with the exposed actin, along with ATP hydrolyzing to adenosine diphosphate (ADP) and inorganic phosphate (Pi), which could provide the energy to pull the thin filament towards the centre of the sarcomere. Many sarcomeres contracting in series contract the myofibrils, causing shortening of the whole cardiac fibre (Figure 1).\textsuperscript{19,20}

Besides, the Ca\textsuperscript{2+} is critical to generate contraction as myofilament activation and force development is largely dependent on intracellular Ca\textsuperscript{2+}. The degree of myofilament Ca\textsuperscript{2+} sensitivity is dynamically regulated by the Ca\textsuperscript{2+} binding affinity of Tn complex.\textsuperscript{21} TnT mutations account for approximately 15% of genotype-positive HCM cases. This subset of HCM cases is characterized by relatively mild or subclinical hypertrophy with a high incidence of sudden death, which may be associated with increased myofilament Ca\textsuperscript{2+} sensitivity in the mutation.\textsuperscript{22} Which also inspired us that the Ca\textsuperscript{2+} binding affinity of Tn complex may be an integration point to understanding the gene mutation and clinical manifestations.

As mentioned above, the sarcomere contractile cycle is powered by the hydrolysis of ATP relying on the reversible binding of calcium. The HCM has been deemed a ‘disease of the sarcomere’, but the clinical features may be different in the patients even with the same genetic mutation. The growing evidence indicating the LncRNAs participates in the regulation of the complicate network in pathological process of hypertrophy involved the contractile protein expressions, calcium handling and mitochondrial function, which are closely related to the function of sarcomere.

3 | LncRNAs IN REGULATION OF PATHOPHYSIOLOGICAL PROCESS OF CARDIAC HYPERTROPHY

3.1 | LncRNAs reregulate components formation of sarcomere

Nearly, 80% of proteins located in the contractile cardiac myocyte are organized into sarcomeres. While pioneering studies have demonstrated that pathogenic variants of genes encoding sarcomere protein existed among 40%–60% of HCM patients, including β-MHC (MYH7), MYBPC (MYBPC3), troponin T (TNNT2), troponin I (TNNI3), α-tropomyosin (TPM1), myosin regulatory light chain 2 (MYL2), myosin essential light chain (MYL3) and actin (ACTC1).\textsuperscript{1,2} So that the malformation of sarcomere is crucial to pathogenesis of HCM, indicating that particular LncRNAs which have been involved in sarcomere protein expression are considering to participant in the regulation of cardiomyocyte hypertrophy.

LncRNAs, being located in both cytoplasm and nucleus, act as a vital role in HCM, which have been proved the capability to regulate the expressions of sarcomere formatting genes in nuclear, by directly regulation ways. Such as Lnc-Mhrt, encoded by the gene of Myh7, is an inhibitor of pathological hypertrophy, via accessing chromatin remodelling through antagonizes the function of SMARCA4.\textsuperscript{23} Besides, Lnc-Mhrt also could inhibit the expression of myocardin, via targeting miR-145a-5p to finally inhibiting the phosphorylation of KLF4, or altering the intracellular location of HDAC5, working as a negative regulator to the pathogenesis of cardiac hypertrophy (Figure 2).\textsuperscript{24,25} So that, once Lnc-Mhrt is down-regulated, it is some kind of losing the inhibition function of Myh7 expression leading hypertrophic phenotype.

While, lnc-Chaer interferes with polycomb repressive complex 2 (PRC2) to inhibit histone H3 lysine 27 methylation (H3K27) at the promoter regions of genes involved in stress-induced
pathological gene activation to attenuates cardiac hypertrophy. Overexpression of Inc-Chaer would reduce the binding of PRC2 to Myh7 and Acta1 genes, resulting in the elevation of such hypertrophic genes, leading to hypertrophy. The Inc-Chaer KO model demonstrated the capability to resist over-pressure loading induced cardiac hypertrophy.

Therefore, the lncRNAs contributes to maintain the normal expression of hypertrophic genes which are coding foetal contractile isoforms. When cardiomyocytes under pathological stimulations, the level of specific lncRNAs might altering, leading to the re-expression of MYH7 and other related genes causing hypertrophic phenotype.

3.2 | LncRNAs regulate the homoeostasis of mitochondria

Mitochondria is one of the most important organelles in cardiomyocytes. Nearly, all the biological activity is relied on the homoeostasis and normal function of mitochondria. Mitochondria is directly correlated between cardiac workload and oxygen consumption, which occupy ~30% of cardiomyocyte and generate more than 95% of ATP consumed by the heart. Cardiac contraction is powered by ATP administration, which is produced within mitochondria through oxidative phosphorylation process on fatty acid, while glucose oxidation or glycolysis could also supply some energy under hypoxia condition. Mitochondria is the multifunctional cell organelle involved in essential functions of cardiomyocytes, including maintain morphology of cardiomyocyte via mitochondrial dynamics process, reactive oxygen species (ROS) accumulation, calcium transportation by uniporter located on mitochondrial membrane, apart from energy generation. Pathological hypertrophy is associated with mitochondria dysfunction. The emerging evidence suggested that IncRNAs contribute to the synchronization of cellular biological pathways in HCM, via regulating the homoeostasis of mitochondria.

A key research from Song et al demonstrated the role of mitochondrial dynamics process in inducing cardiomyopathy and proved that the impairment of mitochondrial dynamics would lead to cardiac hypertrophy and heart failure. Besides, the mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) double knock out induced more mitochondrial fission, resulting in eccentric hypertrophic modelling. Besides, another research from Papanicolaou et al demonstrated the absence of Mfn2 in cardiomyocyte is associated with delayed mitochondrial permeability transition and local generation of ROS, resulting in cardiac hypertrophy. So that, the homoeostasis of mitochondrial dynamics process is essential to maintain cardiomyocyte normal morphology. Lv et al found that the lnc-Plscr4 participant in the regulation of miR-214-Mfn2 axis to main mitochondrial dynamics process. Their findings revealed the inhibition of lnc-Plscr4 inducing hypertrophy, while overexpression attenuate the hypertrophy both from angiotensin II treated cardiomyocytes and transverse aortic constriction treated mice. Moreover, Anusha et al reviewed that miRNAs were involved in the regulation of mitochondrial dynamics. So that, a series of non-coding RNAs, such as lncRNAs and miRNAs, have been identified to be involved in the mitochondrial dynamics controls, which may be a potential therapeuetic to intervene the cardiac diseases. However, according to common sense, the interactions between enrolled lncRNAs and miRNAs need to be further demonstrated.

Beyond the morphology relationship between mitochondria and cardiomyocyte, the metabolic alternations are another character during cardiac hypertrophy. Metabolic remodelling in pathological hypertrophy with shift from predominant long-chain fatty acid utilization to glucose utilization will result in an shortage in ATP consumption. Carnitine palmitoyl transferase I (CPT1) need to be recruited in the first step in the transportation of fatty acids into mitochondria, which is encoded by CPT1b gene in heart and muscle cells. The activity of CPT1b is considered to guiding fatty acid oxidation. While, Inc-Uc.323 has been documented it could regulate
the expression of CPT1b via interacting with its coactivator of zeste homolog 2 (EZH2), which bound to the promoter of CPT1b via H3K27me3 to induce CPT1b down-regulation, protecting cardiomyocytes against hypertrophy (Figure 2).46 Lnc-Uc.233 depletion mice presented a severe hypertrophic heart, providing evidence on the association between lncRNAs and metabolic disorder in regulation of cardiac hypertrophy.

3.3 | LncRNAs controls the function of calcium channels

Arrhythmia is always combined with HCM, which may be associated with the Ca2+ mishandling. Several studies have identified some gene mutations associated with Ca2+ regulatory which contributed to cardiac hypertrophy, including phospholamban (PLN), ryanodine receptor 2 (RYR2) and junctophilin 2 (JPH2).37 Calcineurin overexpression mice model is a typical standard model to induce HCM. While, it is a strong evidence to emphasize that Ca2+ mishandling is crucial to generate cardiomyocyte hypertrophy. So that the electrical remodelling is also a great part of biological processes changing among HCM.47 Here, we intend to identify the roles of lncRNAs in Ca2+ handling network, which may contribute to hypertrophic phenotype by sustained Ca2+ mishandling induced electrical activity.

During the cardiac action potential, Ca2+ enters the cell and triggers Ca2+ release from the sarcoplasmic reticulum (SR). The raising concentration of Ca2+ in the cytoplasm allowing Ca2+ to bind to the TnC, which then switches on the contractile machinery. Ca2+ transport out of the cytosol for relaxation occurring by four pathways, involving SR Ca2+-ATPase, sarcolemmal Na+/Ca2+ exchange, sarcolemmal Ca2+-ATPase or mitochondrial Ca2+ uniporter.21,39 So that, the dysfunction of four types of Ca2+ channels mentioned above would lead to the pathophysiological process of hypertrophy.

SR ATP-driven Ca2+ pump (SERCA2a) is an enzyme located on the SR membrane that pumps calcium into the SR, and the function of SERCA2a is closely related to calcium transient amplitude and calcium store capacity in cardiac myocytes.40 Lnc-Dach1 (dachshund homolog 1) played as negative role in regulating calcium handling, which binds to SERCA2a and enhances its ubiquitination leading to the reduction of SERCA2a protein and impairing calcium handling and cardiac function (Figure 2).50 The Inc-Dach1 increased in hypertrophic cardiomyocyte and impaired the SERCA2a induced calcium release by RyR2, resulting in weaker contraction and pathological hypertrophic remodelling.

Ca2+-calmodulin-dependent protein kinase II (CaMKII) is associated with phosphorylation of a number of Ca2+- handling proteins with α, β, γ, δ isoforms, relating to the activation of the SERCA2a and RyR2, the disturbing of which would lead inappropriate membrane potential depolarizations, and the higher activity of CaMKII would cause cardiomyocyte hypertrophy.42-45 Lnc-TINCR could regulation the expression of CaMKII via epigenetically silencing, as knockdown of Lnc-TINCR was found to reduce EZH2 occupancy and H3K27me3 binding in the promoter of CaMKII in cardiomyocytes (Figure 2).46 Lnc-H19 as the precursor of miR-675, which inhibit the expression of CaMKII, is a negative regulator of cardiomyocyte hypertrophy (Figure 2).47 Calcineurin is serine/threonine protein phosphatase regulated by CaMKII, which plays an important role in the regulation of pathological hypertrophy.48 Calcineurin could reciprocal repress with miR-133 to regulate cardiac hypertrophy.49 Jiang et al50 found that IncRNA-ROR mediated pathological hypertrophy via decreasing the expression of miR-133, which could influence the handing of calcium.

MEF2 (myocyte enhancer-binding factor 2) family, including MEF2A, MEF2B, MEF2C and MEF2D, have the ability to bind A/T-rich sequences within gene promoter of muscle creatine kinase, which is a critical regulator of cardiac development and cardiac gene expression. MEF2 could mediate Ca2+/calmodulin-dependent signalling to regulate Ca2+ signalling pathway, and regulate mitochondrial genes transcription to involve the bio-function of mitochondrial.51,52 LncRNA-Ahit is a neighbouring gene of MEF2A, which regulate chromatin remodelling via direct binding with SUZ12 (suppressor of zeste 12) and recruiting PRC2 to promote of H3K27me3 on the MEF2A promoter region, resulting against cardiac hypertrophy. Although reduction of MEF2A was the most obvious after down-regulated Ahit, all MEF2 members were induced, including MEF2D.53 MEF2D could regulate the gene NADH dehydrogenase 6 (ND6) expression, which directly modulate complex I activity of mitochondrial, further affecting a number of key mitochondrial functions (Figure 2).54 HDACs act a link role between CaMK and MEF2, in other words, which could act as a media role between calcium handling and mitochondria bio-function.55 LncRNA-MEG3 activated by STAT3 is a positive regulator in pathological hypertrophy through miR-362-5p/HDAC9.56 Thus, LncRNA-Ahit and LncRNA-MEG3 could regulate cardiac hypertrophy involved in the mitochondria bio-function and calcium signal pathway via regulating the integration protein of MEF2.

4 | LncRNA: A POTENTIAL TARGET FOR CARDIAC HYPERTROPHY

The current pharmacologic therapy remains alleviating the symptoms of HCM patients rather than focusing on the underlying cause, such as using β-adrenergic receptor blocker to blunt the heart rate and increase diastolic filling time. With more and more genetic analyses and mechanistic studies positing the sarcomere contraction as a central mediator of cardiac hypertrophy, specific therapies which could regulate the function of sarcomere have been raised up, one of which, named MYK-461 (mavacamten), could selectively reduce myosin ATPase activity and are currently in human clinical trials.57

With much progress been made in elucidating the underlying mechanisms of pathological hypertrophy, many new insights on targeted therapies for cardiac hypertrophy have been proposed. LncRNAs, with the advantages of expressed with tissue and disease specificity, stable in body fluids, and smaller than the coding protein, are more attractive...
as diagnosis biomarkers and therapeutic targets for cardiac hypertrophy. Silenced Lnc-MEG3 or overexpression Lnc-Plscr4 and Lnc-CHAR could attenuate the increasing size of cardiomyocytes induced by angiotensin II (Ang-II). Overexpression of Lnc-H19, Lnc-SNHG1, Lnc-uc.323 or loss-expression of Lnc-Ahit and Lnc-Chast could reduce the cardiomyocytes size in response to phenylephrine. Conditional knockout of Lnc-DACH or overexpression Lnc-TINCR resulted in increasing calcium transient, and improving cardiac function after transverse aortic constriction in mice. Inhibition of Lnc-Chaer expression before the onset of pressure overload substantially attenuates cardiac hypertrophy on mouse model.

5 | VALIDATION OF A LNCRNA-BASED GENE THERAPY ON NON-VIRAL AND VIRAL CONCEPTIONS

Several approaches have been applied to generate the silence and overexpression oligonucleotide for IncRNAs. Simply, the IncRNA siRNA has been used to inhibit the site targeting for IncRNA. Besides, the anti-sense oligonucleotide (ASO) has been widely introduced to impair the function of IncRNAs. Beyond cardiovascular system, the application of ASO for IncRNA has been confirmed a promising therapeutic method for osteoarthritis, hepatopathy disease and cancer. While the IncRNA minics has been used to expression specific oligonucleotide (Table 1). Moreover, some gene-editing method has also been taken into knock out particular IncRNA DNA sequences, such as CRISPR/Cas9 techniques. Based on the oligonucleotide design protocols, researchers were able to demonstrate the capability of IncRNA targeting therapy for cardiac hypertrophy in vivo on small animal models.

These studies have proved the efficient on therapy pathological hypertrophy via gain or loss function of the IncRNAs in vitro or in vivo cardiac hypertrophy model, which supply a new perspective for the treatment of cardiac hypertrophy. Now, a series of microRNAs-based therapies have been applied for clinical trials. However, the lacking of big animal experiments limited the expanded application for IncRNA therapy. Only H19 IncRNA has been tested in pigs to prove the expression of IncRNA H19 increased in two abdominal aortic aneurysm mouse models by a low-density lipoprotein receptor knockout pig model. So that more experiments designed for large animal are essential before launching clinical trials.

However, the simply designed oligonucleotide is not suitable for large mammals' tissue-specific expression. According to the evidence on the confirmation of therapeutic efficacy of IncRNAs on cardiac hypertrophy, newly oligonucleotide delivery system is required to be developed to silence or overexpress a particular IncRNA in cardiovascular system. Typically, there are two novel methods to delivery designed oligonucleotide as viral and non-viral concepts. For the viral concept, several vectors including adenovirus, adeno-associated virus (AAV) and lentivirus (Table 1). While the non-viral concept involved liposomes or nanoparticles approaches to delivery oligonucleotide to heart tissue. Besides, chemical modification, including basic cholesterol modification, 2′-O-(metoxyethyl) (2′MOE), 2′fluoro (2′F), locked nucleic acid and antagomirs strategy, has been widely used for in vivo IncRNA delivery. Beyond IncRNA, AAV seems to be the most promising delivery strategy for continuous expression oligonucleotide in heart tissue. Two researches from William T. Pu's group used AAV to delivery AIP peptides and gene Tafazzin in mice to rescue the pathological phenotype of catecholaminergic polymorphic ventricular tachycardia and Barth syndrome, which has proved the advantages of applying AAV system in gene therapy within cardiovascular system. Besides, the AAV vector has been approved by FDA to clinical application for gene therapy at 2017. At present, more than 30 clinical trials are undergoing on disease treatment of brain, spinal cord, eye, liver and muscle. So that, taking the advantages of various delivery vectors, targeting cardiac hypertrophic IncRNAs would be a potential way to terminate or even reverse pathological hypertrophy remodelling. The Figure 3 demonstrated the common protocol to validate the IncRNA-based gene therapy to clinical applications (Figure 3).
CONCLUSION

Over the past several decades, the molecular mechanisms on cardiac hypertrophy have made a further progression. However, there are still some big dilemmas to fully elucidating the pathological mechanisms for better treatment of cardiac hypertrophy. More and more evidence illustrated that IncRNAs, such as Mhrt, Plscr4 and H19, could act as an important participant in the complicated network in regulating the pathological process of hypertrophy, which involves in the functional homeostasis among sarcomere, mitochondria and intracellular calcium transition, making them as a promising target for treatment of cardiac hypertrophy. This review demonstrated the function of IncRNAs in the processes of pathology hypertrophy, aimed to provide a new insight to explore the pathological mechanisms and to find novel therapeutic targets for disease modulation and prevention in cardiac hypertrophy. Besides, the review presented current strategies to provide gene therapy and the program to validate a IncRNA-based therapeutic approach from bench site to bedside.

ACKNOWLEDGEMENTS

This work was supported by grants from the National Natural Science Foundation of China (No. 81700360).

CONFLICT OF INTEREST

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.

AUTHOR CONTRIBUTIONS

Lei Liu: Conceptualization (supporting); Investigation (lead); Resources (lead); Writing-original draft (equal). Donghui Zhang: Project administration (lead); Supervision (equal); Yifei Li: Conceptualization (lead); Supervision (equal); Validation (equal); Visualization (equal); Writing-original draft (equal); Writing-review & editing (equal). Yifei Li: Conceptualization (lead); Supervision (equal); Validation (equal); Writing-original draft (equal); Writing-review & editing (equal).

ORCID

https://orcid.org/0000-0002-3096-4287

REFERENCES

1. Teekakirikul P, Zhu W, Huang GC, Fung E. Hypertrophic cardiomyopathy: an overview of genetics and management. Biomolecules. 2019;9(12):878.
2. Wolf CM. Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovasc Diagn Ther. 2019;9:5388-5415.
3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363(9424):1881-1891. https://doi.org/10.1016/S0140-6736(04)16358-7.
4. Maron BJ, Maron MS. Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705-715.
5. Helms AS, Alvarado FJ, Yob J, et al. Genotype-dependent and independent calcium signaling dysregulation in human hypertrophic cardiomyopathy. Circulation. 2016;134:1738-1748.
6. Zhou W, Bos JM, Ye D, et al. Induced pluripotent stem cell-derived cardiomyocytes from a patient with MYL2-R58Q-mediated apical hypertrophic cardiomyopathy show hypertrophy, myofibrillar disarray, and calcium perturbations. J Cardiovasc Transl Res. 2019;12:394-403.
7. Sequeira V, Bertero E, Maack C. Energetic drain driving hypertrophic cardiomyopathy. FEBS Lett. 2019;593:1616-1626.
8. Fraysse B, Weinberger F, Bardswell SC, et al. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol. 2012;52:1299-1307.
9. Wijnen PJM, van der Velden J. Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue. Biochim Biophys Acta 2020;1866(8):165774.
10. Yotti R, Seidman CE, Seidman JG. Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies. Annu Rev Genomics Hum Genet. 2019;20:129-153.
11. Wehbe N, Nasser SA, Pintus G, Badran A, Eid AH, Baydoun E. MicroRNAs in cardiac hypertrophy. Int J Mol Sci. 2019;20(9):4714.
12. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145-166.
13. Goff LA, Rinn JL. Linking RNA biology to IncRNAs. Genome Res. 2015;25:1456-1465.
14. Bar C, Chatterjee S, Thum T. Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy. Circulation. 2016;134:1484-1499.
15. Vierreck J, Thum T. Long noncoding RNAs in pathological cardiac remodeling, Circ Res. 2017;120:262-264.
16. Tewari SG, Bugenhagen SM, Palmer BM, Beard DA. Dynamics of cross-bridge cycling, ATP hydrolysis, force generation, and deformation in cardiac muscle. J Mol Cell Cardiol. 2016;96:11-25.
17. Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiac myocytes. Prog Cardiovasc Dis. 2004;47:159-176.
18. Biesiadcki BJ, Westfall MV. Troponin I modulation of cardiac performance: plasticity in the survival switch. Arch Biochem Biophys. 2019;664:9-14.
19. Lin YH, Yap J, Ramachandra CJA, Hausenloy DJ. New insights provided by myofibril mechanics in inherited cardiomyopathies. Cond Med. 2019;2:213-224.
20. Squire J. Special Issue: The actin-myosin interaction in muscle: background and overview. Int J Mol Sci. 2019;20(22):5715.
21. Eisner DA, Caldwell JL, Kistamas K, Trafford AW. Calcium and excitation-contraction coupling in the heart. Circ Res. 2017;121:181-195.
22. Wang L, Kim K, Parikh S, et al. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes. J Mol Cell Cardiol. 2018;114:320-327.
23. Han P, Li W, Lin CH, et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 2014;514:102-106.
24. Xu Y, Luo Y, Liang C, Zhang T. LncRNA-Mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p/KLF4/myocardin axis. J Mol Cell Cardiol. 2020;139:47-61.
25. Luo Y, Xu Y, Liang C, Xing W, Zhang T. The mechanism of myocardial hypertrophy regulated by the interaction between MHRT and myocardin. Cell Signal. 2018;43:11-20.
26. Wang Z, Zhang XJ, Ji YX, et al. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med. 2016;22:1131-1139.
27. Tuomainen T, Tavi P. The role of cardiac energy metabolism in cardiac hypertrophy and failure. Exp Cell Res. 2017;360:12-18.
28. van Oppenheim CJM, den Braven L, Delmar M, van Veen TAB. Mitochondrial dysfunction as substrate for arrhythmogenic cardiomyopathy: a search for new disease mechanisms. Front Physiol. 2019;10:1496.
29. Jusic A, Devaux Y, Action EU-CC. Mitochondrial noncoding RNA-regulatory network in cardiovascular disease. Basic Res Cardiol. 2020;115:23.

30. Song M, Franco A, Fleischer JA, Zhang L, Dorn GW 2nd. Abrogating mitochondrial dynamics in mouse hearts accelerates mitochondrial senescence. Cell Metab. 2017;26:872-883.e5.

31. Papanicolaou KN, Khairallah RJ, Ngoth GA, et al. Mitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. Mol Cell Biol. 2011;31:1309-1328.

32. Sivakumar A, Subbiah R, Balakrishnan R, Rajendhran J. Cardiac mitochondrial dynamics: miR-mediated regulation during cardiac injury. J Mol Cell Cardiol. 2017;110:26-34.

33. Lv L, Li T, Li X, et al. The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214. Mol Ther Nucleic Acids. 2018;10:387-397.

34. Tuunanen H, Knuuti J. Metabolic remodelling in human heart failure. Cardiovasc Res. 2011;90:251-257.

35. van Weeghel M, Abdurrahim D, Nederlof R, et al. Increased cardiac fatty acid oxidation in a mouse model with decreased malonyl-CoA sensitivity of CPT1B. Cardiovasc Res. 2018;114:1324-1334.

36. Sun Y, Fan W, Xue R, et al. Transcribed ultraconserved regions, Uc.323, ameliorates cardiac hypertrophy by regulating the transcription of CPT1b (carotid palmitoyltransferase 1b). Hypertension. 2020;75:79-90.

37. Helms AS, Alvarado FJ, Yob J, et al. Genotype-dependent and independent calcium signaling dysregulation in human hypertrophic cardiomyopathy. Circulation. 2016;134(22):1738-1748.

38. Smith JGW, Owen T, Bhagwan JR, et al. Isogenic pairs of hiPSC-CMs with hypertrophic cardiomyopathy/LVNC-associated ACTC1 E99K mutation unveil differential functional deficits. Stem Cell Reports. 2018;11:1226-1243.

39. Bers DM. Cardiac excitation–contraction coupling. Nature. 2002;415:198-205.

40. Zhihao L, Jingyu N, Lan L, et al. SERCA2a: a key protein in the Ca(2+)-ATPase function. Cell Physiol Biochem. 2019;52:e8732.

41. Cai B, Zhang Y, Zhao Y, et al. Long non-coding RNA-DACH1 regulates cardiac hypertrophy through SUZ12 (suppressor of Zeste 12 protein homolog)-mediated downregulation of MEF2A (myocyte enhancer factor 2A). Circ Heart Fail. 2020;13:e006525.

42. Feng YCJ, Wei B, Wang Y. CaMKII inhibition reduces isoproterenol-induced ischemia and arrhythmias in hypertrophic mice. Oncotarget. 2017;8:17504-17509.

43. Mustroph J, Wagemann O, Lucht CM, et al. Empagliflozin reduces mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and human diseases. Oncotarget. 2017;8:112152-112165.

44. Brusco J, Haas K. Interactions between mitochondria and the transcription factor myocyte enhancer factor 2 (MEF2) regulate neuronal structural and functional plasticity and metabolism. J Physiol. 2015;593:3471-3481.

45. Yu J, Yang Y, Xu Z, et al. Long non-coding RNA Ahit protects against cardiac hypertrophy through SUZ12 (suppressor of Zeste 12 protein homolog)-mediated downregulation of MEF2A (myocyte enhancer factor 2A). Circ Heart Fail. 2020;13:e006525.

46. She H, Yang Q, Shepherd K, et al. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest. 2011;121:930-940.

47. Fong YC, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med. 2000;6:1221-1227.

48. Zhang J, Liang Y, Huang X, et al. STAT3-induced upregulation of IncRNA MEG3 regulates the growth of cardiac hypertrophy through miR-361-5p/HDAC9 axis. Sci Rep. 2019;9:460.

49. Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170:741-748.

50. Zhang M, Jiang J, Guo X, et al. Long non-coding RNA cardiac hypertrophy-associated regulator governs cardiac hypertrophy via regulating miR-20b and the downstream PTEN/PI3K pathway. J Cell Mol Med. 2019;23:7685-7698.

51. Chen X, Gao B, Ponnusamy M, Lin Z, Liu J. MEF2 signaling and transcription factor myocyte enhancer factor 2 (MEF2) regulate neurogenic and functional plasticity and metaplasticity. J Physiol. 2015;593:3471-3481.

52. Dong DL, Chen C, Huo R, et al. Reciprocal repression between miRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension. 2010;55:946-952.

53. Jiang F, Zhou X, Huang J. Long non-coding RNA-ROR mediates the reprogramming in cardiac hypertrophy. PLoS One. 2016;11:e0152767.

54. Chen X, Gao B, Ponnusamy M, Lin Z, Liu J. MEF2 signaling and human diseases. Oncotarget. 2017;8:112152-112165.

55. Chen X, Gao B, Ponnusamy M, Lin Z, Liu J. MEF2 signaling and human diseases. Oncotarget. 2018:10:387-397.

56. Brusco J, Haas K. Interactions between mitochondria and the transcription factor myocyte enhancer factor 2 (MEF2) regulate neuronal structural and functional plasticity and metabolism. J Physiol. 2015;593:3471-3481.

57. Yu J, Yang Y, Xu Z, et al. Long non-coding RNA Ahit protects against cardiac hypertrophy through SUZ12 (suppressor of Zeste 12 protein homolog)-mediated downregulation of MEF2A (myocyte enhancer factor 2A). Circ Heart Fail. 2020;13:e006525.